BDX

Becton, Dickinson and Company

Fundamental data last updated:May 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NYSE

County of HQ

US

Next Earnings Date

08/06/2026

Business Summary

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

 


VALUATION

P/E

35.30

Market Cap ($M USD)

$51.86B

Forward P/E

8.67

PEG

0.03

PRICE TO SALES

2.43

PRICE TO BOOK

1.66

EV / EBITDA

16.41

5-Year Average P/E

Free Cash Flow Yield

6.06%

DCF Value

$1398.85

Graham Number

$88.58

Price to FCF

16.51

EV to FCF

21.75

Earnings Yield

2.83%

FCF Yield

6.06%

DIVIDEND

Yield

2.45%

Annual Payout

$3.51

Payout Ratio

104.13%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$4.06

Next Year EPS Growth Estimate

$16.51

Next Year Revenue Growth Estimate

$2.19T

Return on Equity (ROE)

4.54%

FREE CASH FLOW

Operating Margin

10.61%

Debt-to-Equity

0.76

Piotroski F-Score

8

Altman Z-Score

2.20

Return on Invested Capital (ROIC)

5.36%

Current Ratio

0.94

Quick Ratio

0.55

Net Debt to EBITDA

3.95

Interest Coverage

4.03

Gross Profit margin

46.48%

FCF PER SHARE

$11.20

REVENUE PER SHARE

$76.13

Gainseekers Quantitative Analysis

Summary

Becton, Dickinson and Company is trading at a perplexing discount relative to its DCF value, suggesting the market may be mispricing its long-term potential. The Forward P/E of 9.05 indicates a significant growth expectation, yet the Earnings Yield of 2.71% suggests limited immediate returns. The Altman Z-score of 2.25 raises caution about financial stability, hinting at moderate distress risk. Despite these concerns, the Graham Number suggests undervaluation, pointing to a potential deep value opportunity for discerning investors. Overall, the stock’s valuation presents a complex picture of potential growth tempered by financial caution.

AI Exposure / Tech Reliance

In the rapidly evolving healthcare sector, Becton, Dickinson and Company is well-positioned to leverage AI and technological advancements. As a leader in medical instruments and supplies, the company can integrate AI to enhance product efficiency and patient outcomes. This adaptability ensures resilience against technological disruptions, maintaining its competitive edge.

The Bull Case

For value or GARP investors, BDX offers compelling reasons to buy. The robust ROIC of 5.36% and a Piotroski F-Score of 8 highlight strong operational efficiency and financial health. A solid FCF Yield of 5.80% underscores its ability to generate cash, while a Gross Profit Margin of 46.48% indicates significant pricing power. These metrics collectively paint a picture of a company with efficient capital allocation and a strong competitive position in its industry.

The Bear Case

Despite its strengths, BDX faces notable structural risks. The Price/Book ratio of 1.74 and Price/Sales of 2.53 suggest the stock isn't cheap by traditional value metrics. The Current Ratio of 0.94 and Quick Ratio of 0.55 highlight liquidity concerns, potentially limiting operational flexibility. Additionally, the high Payout Ratio of 104.13% raises red flags about dividend sustainability, indicating potential cash flow constraints.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$173.19

Institutional Ownership %

1-Year Beta

0.29

Insider Buying % (6 Mo)

Distance to 52-Week High

30.88%

Distance to 52-Week Low

10.87%

EARNINGS SURPRISE %

4.32%

50-DAY SMA

$156.52

200-DAY SMA

$154.40

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.